Ubs Group Ag Timber Pharmaceuticals, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
About Timber Pharmaceuticals, Inc.
- Ticker TMBR
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,524,992
- Description
- Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to ...